NCT02730208View on ClinicalTrials.gov

A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions
Cystic Fibrosis
Interventions
DRUG

Tezacaftor/Ivacaftor

TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.

DRUG

Ivacaftor

IVA 150 mg tablet.

DRUG

Placebo

Placebo matched to TEZ/IVA fixed-dose combination tablet.

DRUG

Placebo

Placebo matched to IVA tablet.

Trial Locations (9)

Unknown

Chermside

Melbourne

Nedlands

New Lambton Heights

Parkville SIC

Randwick

South Brisbane

Subiaco

Westmead

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT02730208 - A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation | Biotech Hunter | Biotech Hunter